Takeda Takes Over TiGenix with Key Acquisition

TiGenix was founded in 2000 by Marc Hughes and Walter Fiers, and it was based in Leuven, Belgium.

The company's main focus was on developing and commercializing novel biologic products.

Takeda, a Japanese multinational pharmaceutical company, acquired TiGenix in 2018.

This acquisition marked a significant milestone for TiGenix, as it provided the company with the resources and expertise needed to bring its products to market.

Takeda's acquisition of TiGenix was a strategic move to expand its presence in the regenerative medicine market.

You might enjoy: Sizzle Acquisition

Takeda Pharmaceutical Company acquired TiGenix for up to €520 million ($632 million) in early January 2018.

This acquisition was a significant milestone for TiGenix, which had been through a rollercoaster of a ride since its establishment in 2000.

Takeda's acquisition included the ex-US rights to Cx601, a treatment for complex perianal fistulas in Crohn's disease.

In 2014, TiGenix was already making waves with its Cx601 treatment, with reports suggesting it could be launched as early as 2017.

Takeda completed its acquisition of TiGenix following the expiration of the squeeze-out period, acquiring all outstanding ordinary shares and warrants of the company.

The acquisition marked a major step forward for TiGenix, which had been working on its Cx601 treatment for complex perianal fistulas in patients with Crohn's disease.

TiGenix had been endorsed by Dr. Julian Panés, who had praised the design of the company's Phase III trial of Cx601 during a presentation at the 10th Annual Congress of the European Crohn's and Colitis Organisation (ECCO).

Takeda Pharmaceutical Company completed its acquisition of TiGenix in early 2018, a deal worth up to €520 million ($632 million).

The acquisition was announced in January 2018, marking a significant milestone for both companies.

TiGenix had been a rollercoaster for investors, with ups and downs in the years leading up to the acquisition.

The company's Cx601 treatment was expected to be launched in 2017, but it's unclear if this timeline was met.

Takeda's acquisition of TiGenix was a major move in the pharmaceutical industry, with Takeda gaining a new foothold in the biotechnology space.

Here are some key dates related to the acquisition:

In 2018, Takeda Pharmaceutical Company entered into a licensing agreement for the ex-US rights to Cx601, a treatment for complex perianal fistulas in Crohn's disease.

Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally, which has shown promise in treating complex perianal fistulas in patients with Crohn's disease.

Takeda acquired TiGenix, the company behind Cx601, for up to €520 million in 2018. This acquisition gave Takeda the rights to Cx601 worldwide, except for the US.

Dr. Julian Panés, a renowned expert in Crohn's disease, endorsed the design of the Phase III trial of Cx601, which was a significant milestone in the development of the treatment.

The Phase III trial, known as ADMIRE-CD, was published in a scientific journal, demonstrating the efficacy of Cx601 in treating complex perianal fistulas in patients with Crohn's disease.

Here's a summary of key facts about Cx601:

Takeda and TiGenix announced the results of the Phase 3 ADMIRE-CD trial investigating Cx601, a treatment for complex perianal fistulas in patients with Crohn's disease.

Cx601 is a suspension of allogeneic adipose-derived stem cells injected intra-lesionally.

The Phase 3 ADMIRE-CD trial was published, providing valuable insights into the effectiveness of Cx601.

TiGenix completed the patient recruitment for its Phase III trial of Cx601 in Europe for the treatment of complex perianal fistulas in Crohn's patients.

The trial design for Cx601 was endorsed by the President-Elect of ECCO, a significant milestone for the treatment's development.

TiGenix partnered with Lonza, a global leader in biological and cell therapy manufacturing, to supply its eASC product, Cx601.

Cx601 is an allogeneic expanded adipose-derived stem cells (eASCs) product developed by TiGenix.

TiGenix has obtained a commercial production license for its expanded manufacturing facility in Madrid, allowing for the commercial production of expanded adipose-derived stem cells.

The company's Crohn's disease drug, Cx601, has been granted Swiss orphan drug designation, a designation that provides incentives for the development of treatments for rare diseases.

TiGenix has also announced positive results from the Phase 3 ADMIRE-CD trial investigating Cx601, a suspension of allogeneic adipose-derived stem cells for the treatment of complex perianal fistulas in patients with Crohn's disease.

TiGenix NV has obtained a license for the commercial production of expanded adipose-derived stem cells at its expanded manufacturing facility in Madrid.

This license is a significant milestone for the company, allowing it to scale up production of its stem cell products.

TiGenix NV has been working to expand its manufacturing capabilities to meet growing demand for its stem cell therapies.

The company's expanded manufacturing facility in Madrid will now be able to produce commercial quantities of expanded adipose-derived stem cells.

This development is a key step forward for TiGenix NV as it continues to advance its stem cell therapies for various indications.

TiGenix NV has a strong track record of innovation in the field of stem cell therapy, and this license is a testament to its commitment to bringing new treatments to patients.

Related reading: Takeuchi Manufacturing

TiGenix's Crohn's disease drug, Cx601, has been granted Swiss orphan drug designation. This means that Cx601 will receive benefits and incentives for the development and commercialization of the drug in Switzerland.

Cx601 is a suspension of allogeneic adipose-derived stem cells for the treatment of complex perianal fistulas in patients with Crohn's disease.

The designation was announced by Takeda Pharmaceutical Company Limited and TiGenix NV on August 2, 2016.

TiGenix is a Belgian biopharmaceutical company. It was founded in 2000.

The company's main focus is on developing and commercializing products based on its proprietary chondrocyte implant technology.

This technology allows for the treatment of damaged cartilage in joints.

TiGenix has developed a product called ChondroGuard, which is used to treat cartilage defects.

Their most notable product is Carticel, a chondrocyte-based implant used to treat cartilage defects in the knee.

Carticel was approved in the US in 2006 and in Europe in 2009.